Developing RNAi Therapeutics for Treatment of Cancer & Fibrosis Diseases

READ MORE

LATEST NEWS

April 18, 2021
Sirnaomics Initiates Phase 2 Study Using STP705 for Keloid Scar Prevention Company Expects to Report Interim Clinical Data in the Second Half of 2021 Sirnaomics, Inc.,... READ MORE
February 3, 2021
Sirnaomics to Present at Medical Dermatology Summit Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against... READ MORE
January 17, 2021
Sirnaomics Announces First Patient Dosed In Phase 2a Study of STP705 for Treatment of Cutaneous Basal Cell Carcinoma, Company Expects to Report Initial Clinical Data in 2021 Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against... READ MORE
December 20, 2020
Sirnaomics Reports Positive Data from Phase 2a Study of STP705 for Treatment of Squamous Cell Skin Cancer Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against... READ MORE
December 3, 2020
Sirnaomics to Initiate Phase I Study of STP705 in Treatment of Primary and Metastatic Liver Cancer Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against... READ MORE

Science

Our team uses a consistent, validated approach to develop novel siRNA based therapeutics for significant markets with high unmet clinical need. Using a proprietary algorithm for siRNA sequence prediction against known gene targets we can rapidly identify siRNAs for use against traditionally "non-drugable" targets ...

Read More

Pipeline

Sirnaomics is leveraging an unsurpassed level of knowledge and experience in RNA interference (RNAi) technology and forging a path to high value creation with exciting clinical product development programs in multiple therapeutic areas...

Read More
U.S.A  •  China
© 2007-2021 by Sirnaomics, Inc.
Contact